NASDAQ:LNTH - Lantheus Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.50
  • Forecasted Upside: -0.66 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.05 (0.20%)

This chart shows the closing price for LNTH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lantheus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LNTH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LNTH

Analyst Price Target is $25.50
▼ -0.66% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Lantheus in the last 3 months. The average price target is $25.50, with a high forecast of $31.00 and a low forecast of $20.00. The average price target represents a -0.66% upside from the last price of $25.67.

This chart shows the closing price for LNTH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Lantheus.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/5/2021Credit Suisse GroupBoost Price TargetNeutral$17.00 ➝ $20.00Low
4/28/2021SVB LeerinkBoost Price TargetOutperform$26.00 ➝ $31.00High
2/26/2021Credit Suisse GroupBoost Price TargetNeutral$14.00 ➝ $17.00High
2/26/2021SVB LeerinkBoost Price TargetOutperform$24.00 ➝ $25.00High
2/1/2021SVB LeerinkInitiated CoverageOutperform$24.00Low
12/29/2020Credit Suisse GroupLower Price TargetNeutral$16.00 ➝ $14.00N/A
6/29/2020Jefferies Financial GroupInitiated CoverageBuy$29.00High
6/16/2020CJS SecuritiesUpgradeMarket Perform ➝ OutperformMedium
8/16/2019CJS SecuritiesUpgradeMarket Perform ➝ OutperformHigh
8/2/2018Wells Fargo & CompanyLower Price TargetOutperform$26.00 ➝ $20.00High
8/2/2018Credit Suisse GroupLower Price TargetNeutral ➝ Neutral$23.00 ➝ $21.00High
11/3/2017Jefferies Financial GroupBoost Price TargetBuy$22.00 ➝ $27.00N/A
11/3/2017Credit Suisse GroupBoost Price TargetNeutral$19.00 ➝ $23.00N/A
11/2/2017Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformN/A
10/12/2017Jefferies Financial GroupReiterated RatingBuy$22.00N/A
8/2/2017Credit Suisse GroupBoost Price TargetNeutral$14.00 ➝ $19.00N/A
8/2/2017Jefferies Financial GroupReiterated RatingBuy$18.00 ➝ $22.00High
7/17/2017Cantor FitzgeraldInitiated CoverageOverweight$22.00High
6/30/2017Jefferies Financial GroupReiterated RatingBuy$18.00Low
5/3/2017Jefferies Financial GroupBoost Price TargetBuy$15.00 ➝ $18.00Medium
4/26/2017Jefferies Financial GroupReiterated RatingBuy$15.00Medium
11/8/2016Royal Bank of CanadaBoost Price TargetOutperform$6.00 ➝ $12.00N/A
11/3/2016Credit Suisse GroupReiterated RatingHold$9.00N/A
11/3/2016Jefferies Financial GroupReiterated RatingBuy$13.00N/A
9/23/2016Credit Suisse GroupInitiated CoverageNeutral$8.00N/A
8/29/2016Jefferies Financial GroupBoost Price TargetBuy$8.00 ➝ $12.00N/A
8/5/2016Jefferies Financial GroupReiterated RatingBuyN/A
8/5/2016Credit Suisse GroupSet Price TargetHold$4.00N/A
(Data available from 7/25/2016 forward)
Lantheus logo
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical. It provides Thallium-201 to detect cardiovascular disease; Gallium-67 to detect various infections and cancerous tumors; and Quadramet for severe bone pain associated with osteoblastic metastatic bone lesions. The company also develops PyL for prostate cancer; flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroendocrine tumors; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic; 1404, a Tc-99m labeled small molecule; PSMA-AI, an AI-based imaging analysis technology; and leronlimab, an investigational humanized monoclonal antibody. It serves radiopharmacies, PET manufacturing facilities, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM Toyama Chemical Co. Ltd.; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Read More

Today's Range

Now: $25.67
Low: $25.10
High: $25.86

50 Day Range

MA: $25.03
Low: $19.51
High: $28.59

52 Week Range

Now: $25.67
Low: $10.52
High: $28.74


592,247 shs

Average Volume

631,754 shs

Market Capitalization

$1.73 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Lantheus?

The following Wall Street research analysts have issued reports on Lantheus in the last year: Credit Suisse Group AG, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for LNTH.

What is the current price target for Lantheus?

2 Wall Street analysts have set twelve-month price targets for Lantheus in the last year. Their average twelve-month price target is $25.50, suggesting a possible downside of 0.7%. SVB Leerink LLC has the highest price target set, predicting LNTH will reach $31.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $20.00 for Lantheus in the next year.
View the latest price targets for LNTH.

What is the current consensus analyst rating for Lantheus?

Lantheus currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LNTH will outperform the market and that investors should add to their positions of Lantheus.
View the latest ratings for LNTH.

What other companies compete with Lantheus?

How do I contact Lantheus' investor relations team?

Lantheus' physical mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider's listed phone number is 978-671-8001 and its investor relations email address is [email protected] The official website for Lantheus is